Articles related to CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Pirtobrutinib offers a new line of therapy for CLL and SLL patients who have progressed after covalent BTK inhibitors and venetoclax, with a significant overall response rate and manageable adverse events.

Epcoritamab represents a significant breakthrough in the treatment of Richter syndrome, showcasing promising results in patients who have exhausted other therapeutic avenues. Its unique bispecific action heralds a new era in hematologic malignancy management.

In a recent phase 3 trial, a low-dose chemotherapy regimen demonstrated noninferior efficacy to standard-dose regimens in pediatric AML patients, while significantly reducing non-hematologic toxicities, an important consideration in pediatric oncology.

Dr. Zackon’s study reveals a stark 18% difference in mortality rates between Black and White CLL patients, underscoring the profound impact of socioeconomic factors on patient outcomes.

The recent study on FLT3 inhibitor monotherapy brings hope to the field of oncology, particularly for patients with high-risk FLT3-mutated AML. Administered at the stage of molecular failure, the therapy has shown encouraging survival rates.

Discover why CPX-351 extends relapse-free survival but does not significantly alter overall survival in younger AML/MDS patients, as revealed by the UK NCRI AML19 trial.